-
Join HealthLumen at key upcoming rare disease conferences in Q4 2024
HealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.
-
Supporting rare disease patient advocacy with epidemiological insights
Awareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development. Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]
-
The role of precision epidemiology in R&D decision-making: Spotlight on rare genetic diseases
Rare genetic diseases are challenging to treat due to their complexity, the unique nature of each condition, and the – by definition – small numbers of patients affected by each one. Encouragingly for the rare disease community, the field is moving rapidly with a wide variety of innovative therapies being developed, including gene therapy involving […]
-
Securing Europe’s competitiveness in R&D for people living with rare diseases: Key takeaways from Rare Diseases Forum 2024
Background Set against the backdrop of the Belgian Presidency of the Council of the EU, Rare Diseases Forum came to Brussels this year on April 16th, bringing together a wide range of stakeholders to discuss a European rare disease Action Plan that aims to help Europe secure competitiveness in R&D for rare disease therapies. Although […]
